FDA approves Orchard’s Lenmeldy gene therapy for MLD

19 Mar 2024
www.pharmaceutical-technology.com
Gene TherapyDrug ApprovalClinical Study
FDA approves Orchard’s Lenmeldy gene therapy for MLD
Preview
Source: Pharmaceutical Technology
In clinical studies, 85% of children treated with Lenmeldy maintained normal language and performance IQ scores. Credit: BlueBoeing / Shutterstock.com.
FDA approves Orchard’s Lenmeldy gene therapy for MLD
Preview
Source: Pharmaceutical Technology
The US Food and Drug Administration (FDA) has granted approval to Orchard Therapeutics‘ Lenmeldy (atidarsagene autotemcel) gene therapy for use in children with specific forms of metachromatic leukodystrophy (MLD).
This is the first FDA approval for a gene therapy addressing pre-symptomatic late infantile, early juvenile or early symptomatic early juvenile MLD.
Lenmeldy is a single-use, personalised infusion, utilising the patient’s genetically modified hematopoietic stem cells (HSCs) to halt disease progression.
The gene therapy involves collecting HSCs from the patient and modifying them to include functional copies of the ARSA gene.
The modified cells are re-introduced into the patient’s bone marrow where they engraft and produce immune cells that can break down sulfatides, the substances that accumulate harmfully in MLD.
See Also:
Johnson & Johnson’s paediatric HIV-1 treatment secures FDA approval
FDA approves Orchard’s Lenmeldy gene therapy for MLD
Preview
Source: Pharmaceutical Technology
Everest receives Singapore HSA approval for NEFEGAN to treat IgAN
FDA approves Orchard’s Lenmeldy gene therapy for MLD
Preview
Source: Pharmaceutical Technology
Patients must have previously received high-dose chemotherapy to prepare the bone marrow for the modified cells.
The efficacy and safety of the therapy were evaluated based on data from 37 children who participated in two single-arm, open-label clinical trials and an expanded access programme.
Severe motor impairment-free survival, defined as the time from birth to the first appearance of locomotion loss, loss of sitting without support, or mortality, was the primary measure of efficacy.
All children in the treated group with pre-symptomatic late infantile MLD were alive at six years old, in contrast to only 58% in the natural history group.
71% of treated children could walk unassisted at five years of age.
85% of treated children maintained normal language and performance IQ scores, a result not observed in untreated children.
Those with pre-symptomatic early juvenile and early symptomatic early juvenile MLD exhibited a deceleration in motor and cognitive disease progression.
FDA Center for Biologics Evaluation and Research director Peter Marks stated: “This is the first FDA-approved treatment option for children with this rare genetic disease.
“We remain committed to advancing scientific and regulatory principles that enable the efficient development and review of safe, effective and innovative products that have the potential to change patients’ lives.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
FDA approves Orchard’s Lenmeldy gene therapy for MLD
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.